Brainstorm Cell Therapeutics (BCLI) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
BrainStorm Cell Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update
August 13, 2015 6:55 AM EDTHACKENSACK, N.J. and PETACH TIKVAH, Israel, Aug. 13, 2015 /PRNewswire/ --Â BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the second quarter ended June 30, 2015.
"We continue to advance BrainStorm's lead program, NurOwn®, for the treatment of amyotrophic lateral sclerosis," stated Dr. Tony Fiorino, BrainStorm's CEO. "We announced earlier this week the completion of patient enrollment in our randomized, double-blind,... More



